Molecular Biology Reports

, Volume 45, Issue 4, pp 625–631 | Cite as

Fbxw7β is an inducing mediator of dexamethasone-induced skeletal muscle atrophy in vivo with the axis of Fbxw7β-myogenin–atrogenes

  • Kyungshin Shin
  • Young-Gyu Ko
  • Jaemin JeongEmail author
  • Heechung KwonEmail author
Rapid Communication


Muscle atrophy is induced by several pathways, e.g., it can be attributed to inherited cachectic symptoms, genetic disorders, sarcopenia, or chronic side effects of treatments. However, the underlying regulatory mechanisms that contribute to muscle atrophy have not been fully elucidated. In this study, we evaluated the role of Fbxw7β, an ubiquitin E3 ligase, in a dexamethasone-induced muscle atrophy model. In this model, endogenous Fbxw7β was up-regulated; furthermore, the Fbxw7β-myogenin–atrogene axis was upregulated, supporting our previous results linking Fbxw7β to muscle atrophy in vitro. Also, muscle atrophy was associated with the Fbxw7β-myogenin–atrogene axis and the down-regulation of Dach2, a repressor of myogenin. Taken together, these results suggest that the ubiquitin E3 ligase Fbxw7β and the Fbxw7β-myogenin–atrogene axis have important roles in a dexamethasone-induced muscle atrophy model in vivo and in vitro. Additionally, the Fbxw7β-Dach2-myogenin–atrogene axis is a potential mechanism underlying muscle atrophy in cases of abnormal Fbxw7β expression-induced muscle atrophy or myogenic degenerative disease.


Fbxw7β Skeletal muscle atrophy Atrogenes Myogenin Dexamethasone Dach2 



This study was supported by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science and ICT (MSIT), Republic of Korea (1711042677; 1711045548; 1711045553; 1711045555/50534-2017) and by the Radiation Medicine Research Program through the National Research Foundation of Korea (NRF) (NRF-2017M2A2A7A01070970/50043-2017), funded by the Ministry of Science and ICT (MSIT), Republic of Korea.

Compliance with ethical standards

Conflict of interest

There are no potential conflicts of interest relevant to this article to be reported.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed (kirams2014-0063).

Research involving with human and animal participants

This article does not contain any studies with human performed by any of the authors.

Supplementary material

11033_2018_4185_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 KB)


  1. 1.
    Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Bladucci L, Dalton K, Bepler G (2010) Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 11:107CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ebner N, Springer J, Kalantar-Zadeh K, Lainscak M, Doehner W, Anker SD, von Haehling S (2013) Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas 75:199–206CrossRefPubMedGoogle Scholar
  3. 3.
    Visser M (2009) Towards a definition of sarcopenia—results from epidemiologic studies. J Nutr Health Aging 13:713–716CrossRefPubMedGoogle Scholar
  4. 4.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Muscaritoli M, Anker S, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG), cachexia-anorexia in chronic wasting diseases and nutrition in geriatric. Clin Nutr 29:154–159CrossRefPubMedGoogle Scholar
  6. 6.
    Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98:14440–14445CrossRefPubMedGoogle Scholar
  7. 7.
    Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, Segura CT, Leibovitch SA (2008) The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 27:1266–1276CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, Gregorio CC (2002) Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 157:125–316CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kyungshin S, Sang-Gu H, Ik Joon C, Young-Gyu K, Jaemin J, Heechung K (2017) Fbxw7β, E3 ubiquitin ligase, negative regulation of primary myoblast differentiation, proliferation and migration. Animal Sci J 88:712–719CrossRefGoogle Scholar
  10. 10.
    Kyungshin S, Young-Gyu K, Jaemin J, Kwon H (2017) Skeletal muscle atrophy is induced by Fbxw7β via atrogene upregulation. Cell Biol Int 41:213–220CrossRefGoogle Scholar
  11. 11.
    Kukreti H, Amuthavalli K, Harikumar A, Sathiyamoorthy S, Feng PZ, Anantharaj R, Tan SL, Lokireddy S, Bonala S, Sriram S, McFarlane C, Kambadur R, Sharma M (2013) Muscle-specific microRNA1 (miR1) targets Heat Shock Protein 70 (HSP70) during dexamethasone mediated atrophy. J Biol Chem 288:6663–6678CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Qin J, Dua R, Yang YQ, Zhang HQ, Li Q, Liu L, Guan H, Hou J, An XR (2013) Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. Res Vet Sci 94:84–89CrossRefPubMedGoogle Scholar
  13. 13.
    Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ (2007) The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 6:376–385CrossRefPubMedGoogle Scholar
  14. 14.
    Tang H, Macpherson P, Marvin M, Meadows E, Klein WH, Yang XJ, Goldman D (2009) A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. Mol Biol Cell 20:1120–1131CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tang H, Goldman D (2006) Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade. Proc Natl Acad Sci USA 103:16977–16982CrossRefPubMedGoogle Scholar
  16. 16.
    Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, Shelton JM, Backs J, Klein WH, Richardson JA, Bassel-Duby R, Olsen EN (2010) Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143:35–45CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Macpherson PC, Wang X, Goldman D (2011) Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J Cell Biochem 112:2149–2159CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bricceno KV, Sampognaro PJ, Van Meerbeke JP, Sumner CJ, Fischbeck KH, Burnett BG (2012) Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum Mol Genet 21:4448–4459CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Macpherson PCD, Wang X, Goldman D (2011) Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J Cell Biochem 112:2149–2159CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Carlson ME, Conboy MJ, Hsu M, Barchas L, Jeong J, Agrawal A, Mikels AJ, Agrawal S, Schaffer DV, Conboy IM (2009) Relative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responses. Aging Cell 8:676–689CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dong Y, Pan JS, Zhang L (2013) Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS ONE 8:e58554CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass JD (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708CrossRefPubMedGoogle Scholar
  23. 23.
    Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3(11):1014–1019CrossRefPubMedGoogle Scholar
  24. 24.
    Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL (2004) IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 287:E591–E601CrossRefPubMedGoogle Scholar
  25. 25.
    Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197(1):1–10CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Radiation Molecular Diagnosis Research TeamKorea Institute of Radiological and Medical ScienceSeoulRepublic of Korea
  2. 2.Department of BiotechnologyKorea UniversitySeoulRepublic of Korea
  3. 3.Department of Life SciencesKorea UniversitySeoulRepublic of Korea
  4. 4.Department of SurgeryHanyang Unviersity College of MedicineSeoulRepublic of Korea
  5. 5.Division of Radiation Cancer CenterKIRAMSSeoulRepublic of Korea

Personalised recommendations